Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
Written by ι Stock Market Media Group Staff — February 19, 2014
Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company’s pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than ...
Read More →
19
FEB
Share
FDA Approves ABRAXANE® for Pancreatic Cancer, Could Nuvilex’s Treatment Be Next
Written by ι Stock Market Media Group Staff — September 9, 2013
After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in late January, the U.S. Food and Drug Administration (FDA) moved quickly to approve Celgene Corp.’s (NASDAQ: CELG) ABRAXANE® when used in combination with gemcitabine. Celgene announced late last Friday that the FDA has approved its supplemental new drug application of the combination as first-line treatment ...
Read More →
9
SEP
Share
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
Written by ι Stock Market Media Group Staff — August 28, 2013
As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the treatment of advanced, inoperable pancreatic cancer, it looks on while one more big pharmaceutical company produces inferior data to its own. This time it’s Incyte Corporation, a $5.5 billion market cap company that just enjoyed a more than $10 rise in its share price to ...
Read More →
28
AUG
Share
Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation
Written by ι Stock Market Media Group Staff — August 22, 2013
While Eli Lilly’s (NYSE: LLY) cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big pharmaceutical companies are combining their own drugs with gemcitabine in their own clinical trials in an attempt to improve upon the gemcitabine’s effectiveness when that drug is used alone for the treatment of advanced, inoperable pancreatic cancer, but they’re not finding much success. ...
Read More →
22
AUG
Share
